From summit to win-win! FANGZHOU HEALTH (06086), VIGONVITA-B (02630) deepen strategic cooperation in the field of "AI + chronic disease management", jointly building the future of intelligent health industry.

On November 25th, FANGZHOU JIANKE (06086) held the Double 12 Core Partnership Summit (hereinafter referred to as the Partnership Summit) in Guangzhou. The summit, themed "Joining Forces for Win-Win Results, Leading the Future with Intelligence," brought together experts, scholars, partners, frontline practitioners, and other core forces in the Internet medical industry to discuss the path to improving the quality and efficiency of chronic disease management under the wave of artificial intelligence. During the Partnership Summit, a significant moment was the strategic cooperation signing ceremony between FANGZHOU JIANKE and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. (hereinafter referred to as Wangshan Wangshui, 02630). This cooperation is a vivid practice of precise integration of core industry resources with digital technology capabilities and efficient complementation. In the future, the two parties will explore innovative strategies empowered by AI through product pipeline cooperation and digital marketing, injecting powerful momentum into the high-quality development of the health industry. Anchoring the track of "AI + chronic disease management," technology drives strong growth On October 24th, the Ministry of Science and Technology announced the comprehensive implementation of the "artificial intelligence +" action at the press conference on the spirit of the Fourth Plenary Session of the 20th Central Committee of the CPC, empowering various industries comprehensively. On November 4th, the National Health Commission issued the "Implementation Opinions on Promoting and Regulating the Development of 'Artificial Intelligence + Medical Health' Applications," outlining the core goals and implementation path for the development of medical AI in the next five years. The policy support at the national level has pointed out the key development direction for the industry. During the Partnership Summit, Dr. Xie Fangmin, founder, chairman, and CEO of FANGZHOU JIANKE, based on the industry's development trend, delivered an in-depth interpretation of the industrial opportunities brought by policy guidance and technological changes. "AI + healthcare is the most important direction to focus on in the coming years, especially in the current context of the aging population and the increasing trend of chronic diseases among the younger population in China, AI technology is expected to play a key role," emphasized Dr. Xie Fangmin. As a company that has been deeply involved in chronic disease management for many years, FANGZHOU JIANKE has always adhered to the core logic of "solving real problems and bringing real changes" in its exploration and development of "AI + chronic disease management" application scenarios. In the example of the "AI Health Manager" application scenario launched by FANGZHOU JIANKE's platform, when users enter and use the "Report Interpretation" function through a specified entry, the accumulation of the user's trust and loyalty will continue to increase through multiple rounds of questioning and repeated communication, further driving the conversion of commercial value. A set of data illustrates the changes brought about by the application of AI technology - in October this year, the number of users experiencing AI functions on FANGZHOU JIANKE's platform was 2.4 times higher compared to September, and the Gross Merchandise Volume (GMV) increased significantly by 50%. In the view of Dr. Xie Fangmin, solidifying the foundation of AI technology should not only bring "quality growth" to the business but also address the pain points in traditional management models such as "hospitals are difficult to manage and families cannot manage." It is important to find key breakthroughs to allow more people to enjoy more professional and efficient health services. Dr. Xie Fangmin stated, "To achieve this goal, it is far from enough for businesses to make single-point efforts alone. I am looking forward to working together with industry partners to create a series of replicable and promotable 'AI + chronic disease management' digital solutions, promoting the health industry towards a new stage of high-quality development." Joining forces to achieve full-chain digital upgrade of health services In the current era where the wave of artificial intelligence is sweeping globally and digital technology is reshaping industry configurations, the medical and health industry is entering a new period of ecological synergy and deep integration. Disruptive technological innovation not only reshapes the industry landscape but also gives rise to a fusion paradigm of "technology + industry" and "product + service." At the Partnership Summit, FANGZHOU JIANKE officially announced a strategic partnership with Wangshan Wangshui. This partnership is not just a simple overlapping of resources but is based on the trends of industry development and core user demands, aiming to break industry barriers. By deeply integrating technological empowerment with product pipeline advantages, the goal is to achieve a full-chain upgrade from drug supply to health services. According to the introduction, FANGZHOU JIANKE has a technological advantage in the field of "AI + chronic disease management," application scenario development capability, and full-chain service capability, while Wangshan Wangshui has deep research and product pipeline accumulation in the biopharmaceutical field. Starting from this strategic agreement, the two parties will deeply collaborate based on their respective core strengths to jointly build a "customer-centric" health service system, dedicated to providing accurate, efficient, convenient, and professionally standardized full-lifecycle health management solutions to a wide range of users. Dr. Tian Guanghui, Chairman and General Manager of Wangshan Wangshui, is full of anticipation for the prospects of this cooperation. He stated, "FANGZHOU JIANKE's achievements in 'AI + chronic disease management' and digital marketing fields are evident. Its exploration spirit of using technological innovation to solve industry pain points aligns closely with Wangshan Wangshui's business service philosophy. With this strategic cooperation, we look forward to bridging the key links between biopharmaceutical research and development and health services, allowing research results to more accurately match user needs and efficiently reaching households with high-quality medical products and professional health services through digital means." In the context of the increasingly clear development path of "artificial intelligence +" at the national level, the convening of this Partnership Summit not only showcases FANGZHOU JIANKE's forward-looking layout and technological strength in the field of "AI + chronic disease management" but also constructs an industry synergistic new ecology through strategic agreements. In the future, FANGZHOU JIANKE will continue to deepen its involvement in the field of chronic disease management, solidifying the foundation of technology, strengthening the development of application scenarios, and using technological power to drive the digital upgrade of health services, collaborating with more partners to build a future of inclusive, efficient, and intelligent health industry.